EcoDrugPlus

Rac-Gamma Serine/threonine-Protein Kinase

Ensembl ID : ENSBSLG00000023291
Gene Symbol: LOC114841965
3 Cross references
203 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSBSLG00000011398
Gene Symbol: RAF1
3 Cross references
207 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSBSLG00000025119
Gene Symbol: ROCK1
3 Cross references
212 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSBSLG00000021617
Gene Symbol: ROCK2
3 Cross references
216 Possible Orthologues:

Sem1 26s Proteasome Subunit

Ensembl ID : ENSBSLG00000003587
Gene Symbol: SEM1
1 Cross references
156 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSBSLG00000009053
Gene Symbol: SRC
3 Cross references
191 Possible Orthologues:

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSBSLG00000000754
Gene Symbol: LOC114853302
3 Cross references
204 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSBSLG00000018493
Gene Symbol: TTK
3 Cross references
204 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSBSLG00000009078
Gene Symbol: UGCG
3 Cross references
212 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSBSLG00000019648
Gene Symbol: WEE1
3 Cross references
206 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSBSLG00000005668
Gene Symbol: YES1
3 Cross references
197 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSBSLG00000000978
Gene Symbol: ACHE
3 Cross references
233 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).